舍曲林联用小剂量舒必利治疗躯体形式障碍的疗效观察

Comparative Study of Sulpiride Combined with Sertraline in the Treatment of Somatoform Disorders

目的:研究舍曲林联合小剂量舒必利与单用舍曲林治疗躯体形式障碍的临床疗效。方法:86例躯体形式障碍患者随机分为两组各43例,研究组予舍曲林合并舒必利治疗,对照组单用舍曲林治疗。治疗前与治疗12周后采用汉密尔顿焦虑表(HAMA)、临床疗效总评量表(CGI)、副反应量表(TESS)观察评定;比较2组疗效及不良反应发生率。结果:研究组在治疗后2,4,8,12周的HAMA总分和躯体性焦虑因子分明显低于对照组(P<0.05或0.01),减分率明显高于对照组(P<0.05或0.01)。治疗12周后研究组临床总有效率为83.7%,显著高于对照组58.1%(P<0.01);研究组不良反应发生率为20.9%,对照组为25.6%,2组比较差异无统计学意义(P>0.05)。结论:舍曲林联合舒必利治疗躯体形式障碍较单用舍曲林具有起效快、疗效好等优点。

Objective：To study the clinical effects of sulpiride combined with sertraline and sertraline single on the treatment of somatoform disorders. Methods：86 patients with somatoform disorders were randomly divided into two groups. One group （study group N = 43 ） was treated with sulpiride combined with sertraline and the other group （con- trolled group N = 43 ） , treated with sertraline only. The efficacy and safety were assessed with HAMA, CGI and TESS. The effective rate and side effect rate were compared between the two groups. Results：HAMA total score and HAMA-SOM fac- tor score were significantly lower in sulpiride combined group than those in the controlled group at the end of weeks 2, 4, 8 and 12 of the treatment（ P 〈 0.05 or P 〈 0.01 ）. The effective rate was 83.7% in sulpiride combined group and 58.1% in the controlled group（ P 〈 0.05 ）. The side effect rate was 20.9% in sulpiride combined group and 25.6% in the controlled group. There was no difference between the two groups. Conclusion：Sertraline combined with sulpiride was more effective than sertraline monotherapy in the treatment of somatoform disorders.